Yonsei medical journal
-
Yonsei medical journal · Oct 2022
Retraction Of PublicationRetraction: Paper "Inhibition of Long Noncoding RNA SNHG15 Ameliorates Hypoxia/Ischemia-Induced Neuronal Damage by Regulating miR-302a-3p/STAT1/NF-κB Axis" by Hu C, et al. [Yonsei Med J 2021;62(4):325-337].
This corrects the article on p. 325 in vol. 62, PMID: 33779086.
-
Yonsei medical journal · Jun 2005
Review Retracted PublicationEfficacy of oral etidronate for skeletal diseases in Japan.
Etidronate is an oral bisphosphonate compound that is known to reduce bone resorption through the inhibition of osteoclastic activity. The efficacy of etidronate for involutional (postmenopausal and senile) and glucocorticoid-induced osteoporosis, as well as that for other skeletal diseases, was reviewed in Japanese patients. Cyclical etidronate treatment (200 mg or 400mg/day for 2 weeks about every 3 months) increases the lumbar bone mineral density (BMD) in patients with involutional osteoporosis and prevents incident vertebral fractures in patients with glucocorticoid-induced osteoporosis. ⋯ Oral etidronate treatment may also help to transiently relieve metastatic cancer bone pain followed by a decrease in abnormally raised bone resorption in patients with painful bone metastases from primary cancer sites, such as the lung, breast and prostate. Thus, oral etidronate treatment is suggested to be efficacious for osteoporosis, as well as other skeletal diseases associated with increased bone resorption, in Japanese patients. Randomized controlled trials needed to be conducted on a large number of patients to confirm these effects.
-
Yonsei medical journal · Aug 2009
Randomized Controlled Trial Retracted PublicationComparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.
The comparative effects of alendronate and alfacalcidol on bone mineral density (BMD) and bone turnover have already been established in postmenopausal women with osteoporosis. An open-labeled prospective study was conducted to compare the treatment effects of alendronate and alfacalcidol on hip BMD and bone turnover in Japanese men with osteoporosis or osteopenia with clinical risk factors for fractures. ⋯ The present study confirmed that alendronate has better efficacy than alfacalcidol (active control) in increasing hip BMD and reducing bone turnover in Japanese men with osteoporosis or osteopenia with clinical risk factors for fractures.
-
Yonsei medical journal · Jan 2019
Retraction Of PublicationRetraction: Paper "Combined Treatment with Vitamin K₂ and Bisphosphonate in Postmenopausal Women with Osteoporosis" by Iwamoto J, et al. [Yonsei Med J 2003;44(5):751-756].
This corrects the article on p. 751 in vol. 44, PMID: 14584089.